- Home
- DTIL vs IXHL Comparison
DTIL vs IXHL Comparison
Compare DTIL & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTIL | IXHL |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.0M | 49.1M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | DTIL | IXHL |
|---|---|---|
| Price | $5.02 | $0.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $47.00 | N/A |
| AVG Volume (30 Days) | 198.7K | ★ 24.9M |
| Earning Date | 11-03-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $698,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.61 | $0.08 |
| 52 Week High | $8.82 | $2.25 |
Technical Indicators
Market Signals| Indicator | DTIL | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 57.22 |
| Support Level | $4.61 | $0.38 |
| Resistance Level | $5.20 | $0.50 |
| Average True Range (ATR) | 0.34 | 0.04 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 41.08 | 63.35 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.